Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of ischemia and ischemia-reperfusion injury comprising administration of at least one peptide disclosed herein, or a pharmaceutically acceptable salt thereof.

Abstract: A packaged radio frequency (RF) amplifier device includes a flange and a transistor die mounted to the flange. The transistor die includes an output terminal. The packaged RF amplifier device includes a first bond wire array including a first plurality of bond wires. Each bond wire in the first plurality of bond wires is electrically coupled to the output terminal of the transistor die. A first ground loop area of a first bond wire in the first plurality of bond wires is greater than a second ground loop area of a second bond wire in the first plurality of bond wires.

Abstract: A floor for use with a glass elevator is provided. The floor includes an upper major surface, a lower major surface opposing the upper major surface, a first side edge, a second side edge, the first and second side edges extending from the upper major surface to the lower major surface. The floor includes one or more front edges and one or more rear edges. The one or more front edges and one or more rear edges extend from the upper major surface to the lower major surface. The floor is formed from a unitary, continuous, solid plate material.

Abstract: The present invention provides compounds of formula (I), wherein: R1 is unsubstituted C1-C6 alkyl; La is substituted or unsubstituted C1-C6 alkyl linker, substituted or unsubstituted C3-C10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and R2 and R3 are each, independently, H, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C6-C10 aryl; or alternatively, R2 and R3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S.

Abstract: A packaged radio frequency (RF) amplifier device includes a flange and a transistor die mounted to the flange. The transistor die includes an output terminal. The packaged RF amplifier device includes a first bond wire array including a first plurality of bond wires. Each bond wire in the first plurality of bond wires is electrically coupled to the output terminal of the transistor die. A first ground loop area of a first bond wire in the first plurality of bond wires is greater than a second ground loop area of a second bond wire in the first plurality of bond wires.

Abstract: A hardware product for creating a light ring and a dead front effect. The product may include a housing with an opening. The hardware product may also include a button positioned within the opening and configured to be depressed by a user. The button is constructed using a two-part molding process and includes a first shot and a second shot. The first shot is configured to disperse light around the perimeter shape of the opening. The second shot is constructed from an optically opaque or semi-opaque material A single light-emitting component electrically coupled to the circuit board provides light for creating the light ring.

Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

Abstract: Embodiments of Doherty Power Amplifier (PA) and other PA packages are provided, as are systems including PA packages. In embodiments, the PA package includes a package body having a longitudinal axis, a first group of input-side leads projecting from a first side of the package body and having an intra-group lead spacing, and a first group of output-side leads projecting from a second side of the package body and also having the intra-group lead spacing. A first carrier input lead projects from the first package body side and is spaced from the first group of input-side leads by an input-side isolation gap, which has a width exceeding the intra-group lead spacing. Similarly, a first carrier output lead projects from the second package body side, is laterally aligned with the first carrier input lead, and is separated from the first group of output-side leads by an output-side isolation gap.

Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.